Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia

Daniel A. Pollyea; John Barrett; Courtney D. DiNardo; Laura C. Michaelis; Gail J. Roboz; Robert Q. Le; Kelly J. Norsworthy; R. Angelo de Claro; Marc R. Theoret; Richard Pazdur

doi:10.1158/1078-0432.CCR-21-2124

Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia

Daniel A. Pollyea, John Barrett, Courtney D. DiNardo, Laura C. Michaelis, Gail J. Roboz, Robert Q. Le, Kelly J. Norsworthy, R. Angelo de Claro, Marc R. Theoret, Richard Pazdur

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The Food and Drug Administration Oncology Center of Excellence initiated Project 2025 to develop 5-year goals in specific areas of oncology drug development. This meeting, in October 2020, brought together a panel of regulators and academic experts in acute myeloid leukemia (AML) to discuss opportunities to maximize the success that has recently occurred in AML drug development. The panel discussed challenges and opportunities in clinical trial design and novel endpoints, and outlined key considerations for drug development to facilitate continued growth in the field.

Original language	English (US)
Pages (from-to)	816-820
Number of pages	5
Journal	Clinical Cancer Research
Volume	28
Issue number	5
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-2124
State	Published - Mar 1 2022
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-21-2124

Cite this

@article{c15e307c7c0444c8b40c4288087b8d41,

title = "Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia",

abstract = "The Food and Drug Administration Oncology Center of Excellence initiated Project 2025 to develop 5-year goals in specific areas of oncology drug development. This meeting, in October 2020, brought together a panel of regulators and academic experts in acute myeloid leukemia (AML) to discuss opportunities to maximize the success that has recently occurred in AML drug development. The panel discussed challenges and opportunities in clinical trial design and novel endpoints, and outlined key considerations for drug development to facilitate continued growth in the field.",

author = "Pollyea, {Daniel A.} and John Barrett and DiNardo, {Courtney D.} and Michaelis, {Laura C.} and Roboz, {Gail J.} and Le, {Robert Q.} and Norsworthy, {Kelly J.} and {de Claro}, {R. Angelo} and Theoret, {Marc R.} and Richard Pazdur",

note = "Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",

year = "2022",

month = mar,

day = "1",

doi = "10.1158/1078-0432.CCR-21-2124",

language = "English (US)",

volume = "28",

pages = "816--820",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "5",

}

TY - JOUR

T1 - Project 2025

T2 - Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia

AU - Pollyea, Daniel A.

AU - Barrett, John

AU - DiNardo, Courtney D.

AU - Michaelis, Laura C.

AU - Roboz, Gail J.

AU - Le, Robert Q.

AU - Norsworthy, Kelly J.

AU - de Claro, R. Angelo

AU - Theoret, Marc R.

AU - Pazdur, Richard

PY - 2022/3/1

Y1 - 2022/3/1

N2 - The Food and Drug Administration Oncology Center of Excellence initiated Project 2025 to develop 5-year goals in specific areas of oncology drug development. This meeting, in October 2020, brought together a panel of regulators and academic experts in acute myeloid leukemia (AML) to discuss opportunities to maximize the success that has recently occurred in AML drug development. The panel discussed challenges and opportunities in clinical trial design and novel endpoints, and outlined key considerations for drug development to facilitate continued growth in the field.

AB - The Food and Drug Administration Oncology Center of Excellence initiated Project 2025 to develop 5-year goals in specific areas of oncology drug development. This meeting, in October 2020, brought together a panel of regulators and academic experts in acute myeloid leukemia (AML) to discuss opportunities to maximize the success that has recently occurred in AML drug development. The panel discussed challenges and opportunities in clinical trial design and novel endpoints, and outlined key considerations for drug development to facilitate continued growth in the field.

UR - http://www.scopus.com/inward/record.url?scp=85125723561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125723561&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-21-2124

DO - 10.1158/1078-0432.CCR-21-2124

M3 - Article

C2 - 34753779

AN - SCOPUS:85125723561

SN - 1078-0432

VL - 28

SP - 816

EP - 820

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 5

ER -

Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this